Core Insights - The National Healthcare Security Administration (NHSA) has officially announced the latest version of the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, which includes 114 new drugs and 19 drugs in the first version of the Commercial Health Insurance Innovative Drug Catalog, effective from January 1, 2026 [1][2][3] Industry Summary - The NHSA has adjusted the drug catalog for the eighth time since its establishment, with a total of 949 new drugs added over the years, and the medical insurance fund has spent over 4.6 trillion RMB on negotiated drugs, driving sales exceeding 6 trillion RMB [1][2] - The new catalog includes 50 first-class innovative drugs, with an overall success rate of 88%, significantly higher than the 76% in 2024 [3] - The inclusion of drugs for major diseases such as triple-negative breast cancer, pancreatic cancer, and lung cancer, as well as rare diseases and chronic conditions, addresses gaps in basic medical insurance coverage [2][3] Company-Specific Updates - Green Leaf Pharmaceutical has successfully included five new products in the NHSA's drug catalog, including MiMeiXin® and ZhanBiJia® [4] - Fuhong Hanlin announced that its product Fuzhuoning® has been included in the NHSA's drug catalog for specific indications [5] - Junshi Biosciences reported that its products Tuoyi® and Junshida® have been successfully included in the NHSA's drug catalog [6] - Innovent Biologics has successfully added seven innovative products to the new NHSA drug catalog, including Daboru® and Xindimian® [6]

Core Viewpoint - The company, Fuhong Hanlin (02696), announced that its drug, Fuzhuoning® (Acalabrutinib), has been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) under Category B, specifically for use in hormone receptor-positive, HER2-negative recurrent or metastatic breast cancer patients who have experienced disease progression after endocrine therapy [1] Group 1 - Fuzhuoning® is an innovative CDK4/6 small molecule inhibitor licensed by the company [1] - The drug was approved for marketing in China in May 2025, with its first indication being in combination with Fulvestrant for hormone receptor-positive, HER2-negative recurrent or metastatic breast cancer patients who have previously received endocrine therapy [1] - In September 2025, Fuzhuoning® received an additional indication for use in hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer in adult patients, in combination with aromatase inhibitors as initial endocrine therapy [1] Group 2 - The new National Medical Insurance Drug Catalog will officially take effect on January 1, 2026 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 自願公告 複妥寧® （枸櫞酸伏維西利膠囊）獲納入國家醫保藥品目錄 A. 緒言 本公告由上海復宏漢霖生物技術股份有限公司（「本公司」）自願作出，以告知 本公司股東及潛在投資者本公司最新業務更新。 B. 關於複妥寧® 複妥寧®係本公司許可引進的創新型CDK4/6小分子抑制劑。2025年5月，於 中國境內獲批上市，首次獲批適應症為聯合氟維司群用於既往接受內分泌治 療後出現疾病進展的激素受體(HR)陽性、人表皮生長因子受體2(HER2)陰性 的複發或轉移性成年乳腺癌患者；2025年9月，複妥寧®於中國境內新增獲批 一項適應症，用於激素受體(HR)陽性、人表皮生長因子受體2(HER2)陰性局 部晚期或轉移性乳腺癌成人患者：與芳香化酶抑制劑聯合使用作為初始 ...